← All trials
NCT04205357
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2020
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BergenLead sponsor
- Cornell UniversityCollaborator
- University of StavangerCollaborator
- Northwell HealthCollaborator
- University of BergenCollaborator
- Norwegian Cancer SocietyCollaborator
- University of BergenOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.